Insight

Jan 19, 2025, 14:02

Cristina L.: Anti-GD2 Immunotherapy in retinoblastoma

Cristina L., Specialist doctor at Sant Joan de Déu Hospital Barcelona, shared on LinkedIn:

“Anti-GD2 Immunotherapy in retinoblastoma.

We report two cases of metastatic retinoblastoma in patients unable to complete full-dose chemotherapy due to prior toxicities.

Following treatment with naxitamab, intrathecal topotecan, and reduced-intensity myeloablative chemotherapy, they achieved 4 and 5 years of disease-free survival after metastatic relapse.

Could this combination signal a safer, more effective path forward for high-risk RB patients?”

Case Report: Successful treatment of metastatic retinoblastoma with CNS involvement with anti-GD2 immunotherapy, intrathecal topotecan and reduced systemic chemotherapy

Authors: Cristina Larrosa, Margarida Simao-Rafael, Noelia Salvador, Juan Pablo Muñoz, Cinzia Lavarino, Guillermo Chantada, Jaume Mora

Cristina L.

cancer Cinzia Lavarino Cristina L. Cristina Larrosa Guillermo Chantada Jaume Mora Juan Pablo Muñoz Margarida Simao-Rafael myeloablative chemotherapy naxitamab Noelia Salvador OncoDaily Oncology Retinoblastoma topotecan

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology